Diabetes

Mylan, Biocon Launch Insulin Glargine Biosimilar in the United Kingdom

November 23rd 2018

By Samantha DiGrande

Article

Mylan and Biocon jointly announced earlier this month that their biosimilar insulin glargine, sold as Semglee and referencing Lantus, has launched in the United Kingdom.

Congressional Report Makes Recommendations to Decrease Insulin Prices, Includes Follow-on Products

November 3rd 2018

By Samantha DiGrande

Article

In a recently published bipartisan report, representatives Diana DeGette, D-Colorado, and Tom Reed, R-New York, co-chairs of the Congressional Diabetes Caucus, released findings from a year-long inquiry into the sources of ever-increasing insulin prices.

Study: Biosimilars Could Drastically Reduce the Cost of Insulin

October 5th 2018

By Kelly Davio

Article

“Comparison of estimated prices with recent government procurement prices suggests that robust competition in the human insulin and insulin analogue market would lead to sizeable savings in most countries and that current manufacturers could set significantly lower prices while still making a profit,” write the study’s authors.

Follow-On Insulin Glargine Shows Similar Safety, Efficacy to Lantus in T1D

August 14th 2018

By Kelly Davio

Article

While US patients with diabetes await the launch of the follow-on, which is expected to offer a welcome cost-savings, newly published data from a 52-week clinical trial in patients with type 1 diabetes (T1D) underscore its similar safety and efficacy to the reference insulin glargine.

Educational Programs on Biosimilar Insulin Benefit Both Patients and Providers

July 18th 2018

By Kelly Davio

Article

At the American Diabetes Association’s 78th Scientific Sessions, researchers presented ways in which education—for both patients and providers—can help improve the care of patients with diabetes who use biosimilar or follow-on insulins.

FDA Rejects Mylan and Biocon's Follow-On Insulin Glargine

June 4th 2018

By Samantha DiGrande

Article

Mylan and its partner Biocon have received a Complete Response Letter from the FDA in regard to their application for a follow-on insulin glargine referencing Lantus.

ADA Gives Recommendations Improve Insulin Affordability, Includes Follow-On Products

May 31st 2018

By Samantha DiGrande

Article

Recently, the American Diabetes Association (ADA) released a set of policy recommendations to improve patient access to much-needed insulin and to lower the substantial cost to treat diabetes.

No Difference in Quality of Glycemic Control With Biosimilar Versus Originator Insulin

May 22nd 2018

By Jackie Syrop

Article

An Asian study comparing the quality of glycemic control among patients using biosimilar insulin with those using originator insulin found no independent association of biosimilar insulin with differences in indicators of glycemic control—glycated hemoglobin, insulin dosage, or hypoglycemia.

Mylan's Insulin Glargine Follow-on Safe and Effective in Treating Type 1 Diabetes

May 14th 2018

By Kelly Davio

Article

Mylan’s insulin glargine follow-on, MYL-1501D, referencing Sanofi’s Lantus, is a long-acting human insulin analogue that allows for once-daily basal use in patients with type 1 diabetes. The drug has been authorized for marketing as a biosimilar insulin in the European Union and in Australia under the brand name Semglee.

Sanofi Launches Follow-On Insulin Lispro, Admelog

April 9th 2018

By The Center for Biosimilars Staff

Article

Sanofi’s list prices for Admelog are approximately 15% lower than the originator Humalog’s prices.